Although often mentioned as an area in which Product-Service-Systems (PSS) possess great potential, the health care sector has not been in the focus of research in the past. This paper briefly reviews the challenges and benefits of implementing PSS and analyses the special characteristics of the health care market. A case study is then reported in which a PSS approach has been developed for a business-to-business, as well as a business-to-customer, scenario, in order to establish and then grow a market for an innovative method to treat brain tumours and neurodegenerative diseases.
Introduction
specialized physicians along the diagnostic and therapeutic workflow (e.g. radiologists for diagnosis, medical oncologists, radiotherapists and surgeons for treatment of cancer). The patients as "end user" form the basic layer of actors in the market, creating the actual need for a specific diagnostic or therapeutic procedure. Considering the potentially high risks, regulatory bodies require a proof of safety and efficacy to be documented by the approval-requesting company in order to approve the marketing of drugs, medial devices or services. Compliance to all applicable regulatory standards is mandatory for any provider of products or services to enter the market 1 .
Governmental regulatory authorities like the Food and Drug Administration (FDA) in the United States influence development costs for drugs, medical devices or services by setting the standards, requirements and restrictions for R&D. Governmental authorities can also shift the focus of R&D within companies by special regulations, An example of this is an accelerated approval process for technology to treat "orphan diseases" (e.g. rare diseases with small patient population) , if the unmet medical need is higher than the incentive of the market [8] . Therefore, governmental policies clearly influence the market and its players in the health care sector.
Insurance programs and companies play another major role in defining the framework of the market. Governmental health care insurance programs such as MEDICARE in the U.S. steer the market by their reimbursement policies. Besides the proof of safety and efficacy, those institutions also require additional information of the costs and benefits resulting from the adoption of a new treatment approach, compared to "standard care".
The reimbursement of drugs and procedures has a direct impact on the R&D strategy of technology providers. Studies showed that pharmaceutical companies tend to directly reinvest revenue into new R&D programs (Smith and Summers).
The drug pricing set by MEDICARE or other payors affects the expected revenue and therefore has an impact on amount of money invested in R&D and as a consequence on the timelines of development programs.
Pharmaceutical companies as well as medical device companies are driven by market incentives and primarily try to maximize their return on invest. Those companies usually have to manage significant risks during the R&D phases of a drug.
The development process is divided into pre-clinical and clinical phases. The ratio of drug candidates entering the first clinical (human) phase and the succeeding therapeutics actually entering the market is only slightly above 10 to 1 in the treatment field of central nervous system (CNS) and only little higher in other areas [9] .
Time to market usually has a direct impact on the revenue of pharmaceutical companies. Potential products are usually first protected in a patent and then further developed to enter the market. Therefore, shorter the development time, the longer is the monopolistic period on the market, which leads to significantly higher profitability of the drug.
Health care providers such as physicians primarily have the goal to treat patents in the best possible way. This group of players in the market can be a huge resource for the industry in R&D as well as marketing. Based on their specialized medical knowledge and their experience in daily clinical routine, physicians are the biggest source of new ideas.
Once those ideas are taken up by the industry, physicians are facilitating the creation of the mandatory data for verification and validation of new products. As a reward for this support, physicians can improve their standing as part of the research community (e.g. by publishing results about new treatment technologies).
Being the experts and opinion leaders in their specific field of research, they also have the potential of being a marketing and lobbying resource for pharmaceutical or medical device companies, educating colleagues, but also regulatory authorities and insurance companies, on advantages of new products.
Patients as the inner core of the market initially create the medical need. In the past, they played a quite passive role in the market, but due to better availability and transparency within the health care market, patients may now actively decide on which physician or institution they choose. Having better access to information about latest developments, patients also want to be part of the treatment decisions and stimulate health care providers to constantly improve quality of care.
Derived from the individual goals of each actor, dependencies between such actors can be identified (see Table 2 ). Those dependences need to be considered in PSS design. 
Product Service Systems in Health Care
The health care sector is frequently mentioned in PSS research to be one of the areas where the combination of tangible products and intangible services appears to offer great opportunity for innovation and improvement [4] . However, actual case studies are lacking in the literature.
Nevertheless, the health care sector is facing the same trends towards servitization as other industry sectors, -in some cases to an even higher degree. Therefore, it appears appropriate to analyse the specific implications for this sector.
Despite the lack of academic research, big medical device companies like General Electric Medical Systems were eager to adopt PSS concepts at an early stage [10] .
This strategic transition, however, proved to be a formidable challenge even for such big, well managed companies.
As in other industry sectors, globalisation and its secondary effects have its impact on players in the health care sector. Being in a much more competitive market, the need to differentiate becomes increasingly crucial.
Spending on health care, projected to be 16,2% of the growth domestic product (GDP) in the United States (2007), has grown consistently faster than the overall economy since the 1960s [11] . However, owing to this explosion of costs in health care, the pressure to reduce cost can be considered to be significantly higher than in other areas.
The medical sector, being one of the most innovative segments, is facing an accelerating trend to specialization. Since knowledge rapidly increases and diagnosis as well as treatment gets more and more patient specific, the whole network of actors is gaining complexity.
"Integration" therefore becomes a significant value proposition, which, however, often is a multi-dimensional challenge. The integration of a product into a, for example clinical, workflow is one of those dimensions, often requiring additional services such as consulting, training and education.
Another integration is that of products into other tangible products. Those products may not only include devices but also combinations of drugs and devices, where malfunctions of the whole systems have to be eliminated.
Last but not least, products (e.g. operating rooms) may need to be integrated into, for example hospital, infrastructure for optimal usage. market by creating user acceptance. Added services increase the confidence in using new technologies and therefore PSS can reach a certain threshold of security in opening a market, while an innovative product on its own may not reach this level of user acceptance.
From PSS provider points of view, this decreases economic risks associated with innovative developments, since the combination of products and services may enhance the market penetration and increase the user base.
Case Study: Convection-Enhanced Delivery

Methodology and Sectoral-Relevance of the Case Study
The seven-step methodology suggested by Morelli (see section 1.3) has been followed in this case study for the definition of value proposition, a market analysis, the product/service definition and a use-case analysis.
Especially for the business-to-business PSS, the testing phase, followed by the final definition, is replaced by individual discussions with contract partners (in this case pharmaceutical companies). Instead of having the market challenging the system, the PSS has to be individually tailored to a specific customer. In this case study only the generic part of the development is reported.
Major parts of the business-to-business model outlined in the presented case study have been applied in a collaboration between pharmaceutical company A and medical device company B (see Table 3 ) to carry out an multinational clinical trial. This initial model was then modified based on a retrospective analysis of the collaboration. The enhanced model has been validated in several expert discussions, between medical device company B and pharmaceutical companies similar to pharmaceutical company A with regards to business relevant variables.
The business-to-customer model has been developed based on expert discussions between pharmaceutical company A and medical device company B, validated in subsequent expert discussions between medical device company B and pharmaceutical companies substantially similar to pharmaceutical company A. The following case study refers to direct, convection-enhanced delivery of therapeutic agents into brain tissue to treat aggressive brain tumours or neurodegenerative diseases.
This innovative treatment method requires a highly interdisciplinary approach to transfer it from research to market [12] . As the treatment includes drugs as well as several medical devices, results of this case study should widely be applicable for the more generic, emerging segment of drug-device combinations.
This combination of drugs and medical devices is a recent trend in the health care sector [13] . This is particularly true for the field of local delivery, which necessitates that pharmaceutical companies and medical device manufacturers to work jointly on the research and development issues [14] . In contrast to systemic delivery of therapeutics, where drugs are given by pills or intravenous injection, local drug delivery allows the drug to be placed exactly at the location in the body where it is needed. This leads to a high therapeutic concentration at the target, while the systemic concentration in the body is relatively low, causing less side effects and toxicity. 
Technological Background
Despite impressive advances in medicine, the treatment of diseases related to the brain such as certain types of aggressive brain tumours and many neurodegenerative diseases still presents one of the biggest areas of unmet medical need. This is mainly due to the fact that the brain is protected by the "blood brain barrier" (BBB), which prevents it from being damaged or poisoned by substances in the human blood stream. While being vital for healthy people, Convection-enhanced delivery (CED) is a promising approach to circumvent the BBB. The drug is delivered directly to the target site within the brain tissue, by placing a catheter into the clinical target and applying a positive pressure gradient to push the drug into the tissue. In practice, this approach, which is superficially simple, has been found to be highly complex, since the distribution of the drug is heavily depending on patient specific anatomical structures and pathology.
Planning therefore is a very crucial part of the procedure and the technique requires a multidisciplinary approach to achieve significant improvement of the patient outcome.
From a technological perspective a tailored system of a safe and effective drug, a patient specific treatment planning system and a dedicated set of devices (such as catheters and pumps) is necessary to ensure the delivery of the correct drug in the correct concentration to the correct target area in a defined period of infusion. The state of the art in this area is represented by catheter systems that promote convection-enhanced diffusion as the infusion mode. Additionally, users, in this case the relevant health-care professionals, need to be trained in the usage of the software and hardware tools provided in order to use them in the most optimum
manner.
An overview of the system is as follows. Several magnetic resonance (MR) image series of the patient's brain are acquired for planning purposes. These scans are loaded into a planning software tool in order to plan the exact locations of the drug target and entry points of catheters placed into the target tissue. This planning must be based on the patient specific imaging data as it has to take in account the individual anatomy and pathology of the patient.
The main target of this pre-operational planning is to make sure that a convective flow is established within the solid tissue of the brain and that no drug leaks into the cerebrospinal fluid (CSF) compartment. Secondly, a maximum coverage of the previously defined clinical target volume is the goal of the planning exercise.
Once the treatment plan is finalized, the required data needs to be transferred to the operating room (OR).
The neurosurgeon will then place the catheters according to the plan using the planning data for navigational purposes. Once all catheters are in place and are connected to the infusion pumps containing the drug, the patient will be scanned again to verify the actual position of the catheters.
For infusion, the patient will be hospitalized for several days to allow the whole drug volume to enter the patient at the required low, constant flow rate. During and after the infusion there may be several control scans to monitor the treatment.
Market Analysis and Value Proposition
As outlined above, a system based on infusion via convection-enhanced diffusion (CED) shows promise as a delivery method for drugs to allow them to reach therapeutic concentrations in a significant volume of the brain.
This approach however is technically very challenging. Considerable research is required to develop tools for the delivery of drugs via catheters placed into the solid target tissue.
The current state of the art is represented by the successful development of a software tool to aid the critical step of pre-operative planning of the infusions.
This has allowed a deeper understanding of the underlying principles to be accumulated by the development team.
Since such knowledge and tools are usually not available within pharmaceutical companies, a joint approach is then required to bring the delivery technology, in combination with a working drug, to the market.
This special technological situation combined with the restrictive regulatory framework leads to two consecutive use cases:
A business-to-business PSS to provide a "one-stop-shop" for pharmaceutical companies to manage clinical development and to open up the market by getting approval for the drug-device combination A business-to-customer PSS to grow market acceptance once the market is opened up by having regulatory approval.
These two cases are discussed in more detail below.
The first scenario is required to open up the market for a drug in combination with the drug infusion systems. In such a scenario, the PSS would mainly be focused on the "business to business" relationship between the medical device company delivering software and hardware tools and the pharmaceutical company providing the drug.
In this scenario, the medical device company has to convince pharmaceutical companies of the potential of the technology. Further, it has to justify, in comparison with current practice, any additional risks associated with aspects of the treatment such as the required surgery.
Identifying information gaps for all actors in the market serves as an indicator of the issues that need to be addressed by suitable PSS in order to enhance the acceptance of the infusion method and create the market. Table 4 shows a list of
Creating this market penetration is obviously of value for both providers of the drug device combination.
Users Analysis
Based on Morelli's proposed methodology, the users of both PSS scenarios have been analysed. In the business-to-business model, a pharmaceutical company in the market of brain tumours would be the customer for the products and services.
In the second business-to-customer model, the customer would be any neurosurgeon who wants to treat brain tumour patients with this specific drugdevice combination. Table 5 shows the results of a users analysis for the business-to-business PSS, where pharmaceutical companies are the user. 
Pharmaceutical companies
Goals
Have approved drugs on the market to effectively treat high-grade brain tumours.
Key Problems
The blood-brain-barrier (BBB) prevents large molecules from entering the brain through the blood cycle.
Problem solving strategies Circumvent the BBB by directly delivering the therapeutic agent to the target tissue within the brain. Table 6 summarizes the analysis of neurosurgeons as the target group for a PSS offered, once the market is created and the drug-device combination is available for routine clinical use. Once the surgical procedure is completed, the infusion of the anti cancer drug will be started at the intensive care station. To monitor the treatment outcome, followup scans are performed. The complexity of treatment planning for such drug infusion techniques requires additional services, such as training of neurosurgeons (to plan and actually place catheters correctly during surgery), radiologists (to acquire the right medical images for the treatment planning) and nurses (to correctly maintain the infusion).
As a single component, like a working drug is not sufficient to treat patients and therefore generate the safety and efficacy data required for market approval, an integrated PSS addressing all these requirements is mandatory to get a drug, delivered with a catheter-based infusion technique, onto the market. Looking at this proposed workflow, the required features of products and services can be recognised. Table 8 lists the key features identified for the planning software in order to facilitate the catheter planning and placement process. Additionally, the following service-oriented features have been identified for the business-to-customer scenario (see Table 9 ): This screening process requires an in-depth understanding of underlying principles of the infusion mode, which can be offered to a pharmaceutical company as a consulting service, using knowledge derived from the knowledge base in R&D.
A significant barrier for pharmaceutical companies to actually use infusion as a delivery method for their molecules is that this technology adds to the complexity to the treatment and, therefore, also to the setup of a clinical trial. By offering services to close gaps of expertise and knowledge, those barriers can be eliminated.
By consulting drug companies on the design of the clinical trial in the planning phase and also the management of the trial, risks of trial failure can be mitigated. 6 given orally or intravenously The analysis of the presented case study suggests that further research on PSS applied in the field of health care is required to identify areas where benefits of PSS match unmet needs in the health care sector. Subsectors within the health care sector will have to be analyzed with regards to potential added benefit by means of PSS. In addition, guidelines for designing and implementing PSS in a health care market environment have to be developed and validated in order to facilitate adoption in the industry.
Conclusions
Product Service Systems in health care have not been in the focus of PSS research in the past, although the concept holds great potential to address major challenges in this sector.
The cost explosion and additional cost pressure resulting from globalization is a serious threat to the industry also in the health care sector. PSS is a useful tool to reduce costs and resources while maximizing the outcome. Companies can capitalize on the knowledge they generate during the research and development process of a product, by selling this knowledge in separate services. In addition, products may also be reused in combination with several different services. This is especially true for software products, which can easily be recombined with services to provide additional benefit for a customer group or to exploit new markets.
Due to the high degree of specialization in medical health care and increased complexity of technology, integration of technologies, products and services becomes a whole field of new service components expected by the customer.
Products (tools) and information have to be available at the right point and in required quality during more complex clinical workflows facing a significant increase of actors and interfaces caused by specialization and digitalization of patient data.
PSS offers the chance to establish an extremely close relationship to the user. This is of special benefit for developers in the health care sector, since the knowledge gap between developers (e.g. engineers or software developers) and physicians is generally quite wide. From a company's perspective PSS creates an access to customers as part of the R&D and quality management processes owing to this close relationship.
In a business-to-business scenario, closer relationships can be established between business partners. Those business relations are more likely to be of a cooperative nature, since PSS ultimately focus on the final benefit for the end user, which streamlines efforts of all partners towards the same goal. This stands in contrast to, for example, supply chain thinking, were each participant in the chain tries to maximize its revenue on the following company in the chain and in fact may not beware of the final customer. Processes can be optimized on a higher level by having this common final goal.
The interdisciplinary approaches required for the success of combinations of drug and drug-delivery techniques set a high requirement on communication between users and developers.
Since PSS causes the designer of those systems to focus on the final customer need, it is a very helpful tool for strategic considerations. The combination of products and services may have the critical mass to establish the market, while a product on its own may face too many barriers. Those barriers for a market entry can be specifically eliminated with additional services. In addition, knowledge created during the development process can be sold as consulting and training services leading to increased revenue but also creating additional benefit for the user.
Once on the market PSS can increase market acceptance compared to a product without supplementary services. Especially in the launch of a PSS, this can lead to a broader base of potential customers, for example if services are offered that educate customers in using a product that usually would just be used by a small group of experts. Additionally, the market penetration can be increased, if services and products are designed for an easier user adoption.
